Bioprexum RTM.ppt

8/17/2019 Bioprexum RTM.ppt

1/19


2/19


3/19


4/19


5/19


6/19

ACEI wasassociatedwith bettersurvival thanARB from 2 to

5 years afterAMI

In patients athih C! ris"

without #$%ACE&Isreduced theris" of thecompositeoutcome of

C! death% MI%stro"e% all&

Addin an ACEinhibitor tostandard medical

therapy improvesoutcomes%includin reducedris" for mortalityand myocardialinfarctions( )ess

evidence supportsa bene*t of ARB

ACEi werefound toprevent newonset '+' anddeath innormoalbuminu

ric people withdiabetes% andcould thereforebe used in thispopulation

ACE inhibitorsassociated

with a sini*cant,-. reduction inall&causemortality%whereas nomortality

reduction couldbe demonstratedwith ARBtreatment


7/19


8/19


9/19


10/19


11/19


12/19


13/19


14/19


15/19


16/19


17/19


18/19

Incidence of ACE-inducedcough in the four treatment

groups

Drug Cilazapril (n=70) Enalapril (n=8) !erindopril (n=7") Imidapril (n=7#) $otal(n="0%)

Cough %# (&8#')CI%&* "&+

%8 (%&,+')CI%&* "&"

# (%0&,#')CI"&7%* %7&

%0 (%"&%#')CI7&%8* &88

+0(%#%')

Dropouts

% %% %+ %% +%

Drop outs included in analsis.isher/s eact test P 1alue = 0&0%CI* con2dence inter1al

3igni2cantl lo4er incidence of cough 4ith perindopril compared 4ith other ACEinhi5itors


19/19

$his prospecti1e* randomized* dou5le-5lind triale1aluated the rate of cough occurring 4ithdi6erent ACE inhi5itors o1er a treatment initiationperiod of # 4ees& In this population% the

incidence of couh in patients receivinperindopril was sini*cantly lower than forother treatments% such as enalapril%cila/april% and imidapril( As 5lood pressurereduction 4as eui1alent in each group* the

author concluded that there is a di6erence5et4een ACE inhi5itors regarding the occurrenceof cough&

Conclusion

Documents

Bioprexum RTM.ppt